Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Alexander Patterson

Showing results (271-280 of 273) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 273 results.
The Annals of Thoracic Surgery|November 17, 2016
The Society of Thoracic Surgeons National Database 2016 Annual ReportJeffrey P Jacobs, David M Shahian, Richard L Prager, et al.
Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 11, 2022
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancerValerie W Rusch, Alan Nicholas, G Alexander Patterson, et al.
Pageof 28

Showing results (271-280 of 273) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 273 results.
The Annals of Thoracic Surgery|November 17, 2016
The Society of Thoracic Surgeons National Database 2016 Annual ReportJeffrey P Jacobs, David M Shahian, Richard L Prager, et al.
Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 11, 2022
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancerValerie W Rusch, Alan Nicholas, G Alexander Patterson, et al.
Pageof 28